Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: A tissue microarray-based study

Acta Histochemica

Volumn 114, Issue 6, 2012, Pages 547-552

  Zhang, Lijie ^a   Liu, Hui ^b   Sun, Lin ^b   Li, Ning ^b   Ding, Huiguo ^b   Zheng, Jie ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Differential diagnosis; Glypican 3; Hepatocellular carcinoma; Tissue microarrays

Indexed keywords

GLYPICAN 3; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER TISSUE; COLORECTAL CARCINOMA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EXCISION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; OVARY ADENOCARCINOMA; PROSTATE ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861672741     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2011.10.003     Document Type: Article

References (33)

1. Anatelli F., Chuang S.T., Yang X.J., Wang H.L. Value of Glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol 2008, 130:219-223.
2. Baumhoer D., Tornillo L., Stadlmann S., Roncalli M., Diamantis E.K., Terracciano L.M. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4387 tissue samples. Am J Clin Pathol 2008, 129:899-906.
3. Befeler A.S., Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609-1619.
4. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
5. Di Tommaso L., Destro A., Seok J.Y., Balladore E., Terracciano L., Sangiovanni A., et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009, 50:746-754.
6. Farooq M., Hwang S.Y., Park M.K., Kim J.C., Kim M.K., Sung Y.K. Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest. Mol Cells 2003, 15:356-360.
7. Filmus J. Glypicans in growth control and cancer. Glycobiology 2001, 11:19R-23R.
8. Filmus J., Selleck S.B. Glypicans: proteoglycans with a surprise. J Clin Invest 2001, 108:497-501.
9. Gligorijević J., Djordjević B., Petrović A., Radirević A., Stojanović S. Expression of CD34 in cirrhotic liver- reliance to dedifferentiation. Vojnosanit Pregl 2010, 67:459-462.
10. Hirohashi S., Blum H.E., Ishak K.J. Hepatocellular carcinoma. WHO: pathology & genetics, tumour of the digestive system 2000, IARC Press, p. 159-72.
11. Hsu H.C., Cheng W., Lai P.L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997, 57:5179-5184.
12. Jakubovic B.D., Jothy S. Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol 2007, 82:184-189.
13. Kakar S., Gown A.M., Goodman Z.D., Ferrell L.D. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 2007, 131:1648-1654.
14. Kandil D., Leiman G., Allegretta M., Trotman W., Pantanowitz L., Goulart R., et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates - a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer (Cancer Cytopathol) 2007, 111:316-322.
15. Kawano Y., Sasaki A., Kai S., Endo Y., Iwaki K., Uchida H., et al. Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 2008, 15:1670-1676.
16. Libbrecht L., Severi T., Cassiman D., Vander Borght S., Pirenne J., Nevens F., et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006, 30:1405-1411.
17. Li M., Choo B., Wong Z.M., Filmus J., Buick R.N. Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells. Exp Cell Res 1997, 235:3-12.
18. Lugli A., Tornillo L., Mirlacher M., Bundi M., Sauter G., Terracciano L.M. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3940 tissue samples. Am J Clin Pathol 2004, 122:721-727.
19. Lu J., Zhou Y., Lin X., Jiang Y., Tian R., Zhang Y., et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009, 4:e8467.
20. Nakatsura T., Yoshitake Y., Senju S., Monji M., Komori H., Motomura Y., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306:16-25.
21. Nocito A., Kononen J., Kallioniemi O.P., Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001, 94:1-5.
22. Peters M.G., Farias E., Colombo L., Filmus J., Puricelli L., Bal de Kier Joffe E. Inhibition of invasion and metasasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat 2003, 80:221-232.
23. Poon D., Anderson B.O., Chen L.T., Tanaka K., Lau W.Y., Van Cutsem E., et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1111-1118.
24. Shirakawa H., Kuronuma T., Nishimura Y., Hasebe T., NakanoM, Gotohda N., et al. Glypican-3 is a useful diagnostic marker form a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009, 34:649-656.
25. Stroescu C., Herlea V., Dragnea A., Popescu I. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointestin Liver Dis 2006, 15:9-14.
26. Thompson Coon J., Rogers G., Hewson P., Wright D., Anderson R., Jackson S., et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008, 98:1166-1175.
27. Wang X.Y., Degos F., Dubois S., Tessiore S., Allegretta M., Guttmann R.D., et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006, 37:1435-1441.
28. Wang Y., Zhang X.H., Guo P., Yan L.N., He D. Tumor microvascular density detected by anti-CD105 and anti-CD34 in hepatocellular carcinoma patients and its predictive value of tumor recurrence after liver transplantation. Sichuan Da Xue Xue Bao Yi Xue Ban 2010, 41:818-821.
29. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006, 14:266-272.
30. Xiang Y.Y., Ladeda V., Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001, 20:7408-7412.
31. Yamauchi N., Watanabe A., Hishinuma M., Ohashi K., Midorikawa Y., Morishita Y., et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005, 18:1591-1598.
32. Yang H.I., Yuen M.F., Chan H.L., Han K.H., Chen P.J., Kim D.Y., et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011, 14. [Epub ahead of print] [PubMed: 21497551].
33. Zhu Z.W., Friess H., Wang L., Abou-Shady M., Zimmermann A., Lander A.D., et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001, 48:558-564.